array(40) {
  [0]=>
  string(4) "7986"
  ["article_id"]=>
  string(4) "7986"
  [1]=>
  string(33) "Health Highlights: March 10, 2020"
  ["article_title"]=>
  string(33) "Health Highlights: March 10, 2020"
  [2]=>
  string(157) "Here are some of the latest health and medical news developments, compiled by the editors of HealthDay:&#nlRapid Testing May Be Keeping Germany's Coronav"
  ["short_description"]=>
  string(157) "Here are some of the latest health and medical news developments, compiled by the editors of HealthDay:&#nlRapid Testing May Be Keeping Germany's Coronav"
  [3]=>
  string(249) "Here are some of the latest health and medical news developments, compiled by the editors of HealthDay:&#nlRapid Testing May Be Keeping Germany's Coronavirus Numbers Low&#nlExperts say that rapid testing is likely why Germany has had just two..."
  ["description"]=>
  string(249) "Here are some of the latest health and medical news developments, compiled by the editors of HealthDay:&#nlRapid Testing May Be Keeping Germany's Coronavirus Numbers Low&#nlExperts say that rapid testing is likely why Germany has had just two..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "5"
  ["rss_id"]=>
  string(1) "5"
  [14]=>
  string(150) "https://www.drugs.com/news/health-highlights-march-10-2020-88834.html?utm_source=ddc&utm_medium=rss&utm_campaign=Health+Highlights%3A+March+10%2C+2020"
  ["blog_url"]=>
  string(150) "https://www.drugs.com/news/health-highlights-march-10-2020-88834.html?utm_source=ddc&utm_medium=rss&utm_campaign=Health+Highlights%3A+March+10%2C+2020"
  [15]=>
  string(19) "2020-03-10 16:03:17"
  ["add_date"]=>
  string(19) "2020-03-10 16:03:17"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-11 16:18:16"
  ["create_at"]=>
  string(19) "2020-03-11 16:18:16"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8136"
  ["article_id"]=>
  string(4) "8136"
  [1]=>
  string(108) "‘Errant products’: TGA fines Caruso, Juice Plus, and bars HK weight loss capsules from entering"
  ["article_title"]=>
  string(108) "‘Errant products’: TGA fines Caruso, Juice Plus, and bars HK weight loss capsules from entering"
  [2]=>
  string(152) "Australiaâs health foods brands Caruso Natural Health and Juice Plus were recently fined for false claims and advertising breaches respectively, the "
  ["short_description"]=>
  string(152) "Australiaâs health foods brands Caruso Natural Health and Juice Plus were recently fined for false claims and advertising breaches respectively, the "
  [3]=>
  string(216) "Australiaâs health foods brands Caruso Natural Health and Juice Plus were recently fined for false claims and advertising breaches respectively, the Therapeutic Goods Administration (TGA) announced in a statement."
  ["description"]=>
  string(216) "Australiaâs health foods brands Caruso Natural Health and Juice Plus were recently fined for false claims and advertising breaches respectively, the Therapeutic Goods Administration (TGA) announced in a statement."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "35"
  ["rss_id"]=>
  string(2) "35"
  [14]=>
  string(199) "https://www.nutraingredients-asia.com/Article/2020/03/10/Errant-products-TGA-fines-Caruso-Juice-Plus-and-bars-HK-weight-loss-capsules-from-entering?utm_source=RSS_Feed&utm_medium=RSS&utm_campaign=RSS"
  ["blog_url"]=>
  string(199) "https://www.nutraingredients-asia.com/Article/2020/03/10/Errant-products-TGA-fines-Caruso-Juice-Plus-and-bars-HK-weight-loss-capsules-from-entering?utm_source=RSS_Feed&utm_medium=RSS&utm_campaign=RSS"
  [15]=>
  string(19) "2020-03-10 09:17:00"
  ["add_date"]=>
  string(19) "2020-03-10 09:17:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-11 16:23:57"
  ["create_at"]=>
  string(19) "2020-03-11 16:23:57"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8141"
  ["article_id"]=>
  string(4) "8141"
  [1]=>
  string(68) "Kala to Take Another Shot at FDA Approval With New Dry Eye Drug Data"
  ["article_title"]=>
  string(68) "Kala to Take Another Shot at FDA Approval With New Dry Eye Drug Data"
  [2]=>
  string(150) "A Kala Pharmaceuticals dry eye disease drug that was rejected by the FDA is now being readied for another regulatory filing based on new data. Last Au"
  ["short_description"]=>
  string(150) "A Kala Pharmaceuticals dry eye disease drug that was rejected by the FDA is now being readied for another regulatory filing based on new data. Last Au"
  [3]=>
  string(353) "A Kala Pharmaceuticals dry eye disease drug that was rejected by the FDA is now being readied for another regulatory filing based on new data. Last August the FDA rejected a Kala (NASDAQ: KALA) product meant to temporarily relieve signs and symptoms of dry eye disease. On Monday the Watertown, MA-based biopharma announced preliminary results […]"
  ["description"]=>
  string(353) "A Kala Pharmaceuticals dry eye disease drug that was rejected by the FDA is now being readied for another regulatory filing based on new data. Last August the FDA rejected a Kala (NASDAQ: KALA) product meant to temporarily relieve signs and symptoms of dry eye disease. On Monday the Watertown, MA-based biopharma announced preliminary results […]"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "36"
  ["rss_id"]=>
  string(2) "36"
  [14]=>
  string(107) "https://xconomy.com/boston/2020/03/09/kala-to-take-another-shot-at-fda-approval-with-new-dry-eye-drug-data/"
  ["blog_url"]=>
  string(107) "https://xconomy.com/boston/2020/03/09/kala-to-take-another-shot-at-fda-approval-with-new-dry-eye-drug-data/"
  [15]=>
  string(19) "2020-03-10 08:14:55"
  ["add_date"]=>
  string(19) "2020-03-10 08:14:55"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-11 16:23:57"
  ["create_at"]=>
  string(19) "2020-03-11 16:23:57"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8573"
  ["article_id"]=>
  string(4) "8573"
  [1]=>
  string(128) "Janssen Announces U.S. FDA Breakthrough Therapy Designation Granted for JNJ-6372 for the Treatment of Non-Small Cell Lung Cancer"
  ["article_title"]=>
  string(128) "Janssen Announces U.S. FDA Breakthrough Therapy Designation Granted for JNJ-6372 for the Treatment of Non-Small Cell Lung Cancer"
  [2]=>
  string(150) "RARITAN, NJ, March 10, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Adm"
  ["short_description"]=>
  string(150) "RARITAN, NJ, March 10, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Adm"
  [3]=>
  string(251) "RARITAN, NJ, March 10, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for JNJ-61186372 (JNJ-6372) for the..."
  ["description"]=>
  string(251) "RARITAN, NJ, March 10, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for JNJ-61186372 (JNJ-6372) for the..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "15"
  ["rss_id"]=>
  string(2) "15"
  [14]=>
  string(300) "https://www.drugs.com/clinical_trials/janssen-announces-u-s-fda-breakthrough-therapy-designation-granted-jnj-6372-non-small-cell-lung-18469.html?utm_source=ddc&utm_medium=rss&utm_campaign=Janssen+Announces+U.S.+FDA+Breakthrough+Therapy+Designation+Granted+for+JNJ-6372+for+the+Treatment+of+Non-Small+"
  ["blog_url"]=>
  string(300) "https://www.drugs.com/clinical_trials/janssen-announces-u-s-fda-breakthrough-therapy-designation-granted-jnj-6372-non-small-cell-lung-18469.html?utm_source=ddc&utm_medium=rss&utm_campaign=Janssen+Announces+U.S.+FDA+Breakthrough+Therapy+Designation+Granted+for+JNJ-6372+for+the+Treatment+of+Non-Small+"
  [15]=>
  string(19) "2020-03-10 08:03:10"
  ["add_date"]=>
  string(19) "2020-03-10 08:03:10"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-31 11:18:05"
  ["create_at"]=>
  string(19) "2020-03-31 11:18:05"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8574"
  ["article_id"]=>
  string(4) "8574"
  [1]=>
  string(121) "CytoDyn Files IND and Protocol for Phase 2 Clinical Trial for Treatment of Coronavirus Patients with Leronlimab (PRO 140)"
  ["article_title"]=>
  string(121) "CytoDyn Files IND and Protocol for Phase 2 Clinical Trial for Treatment of Coronavirus Patients with Leronlimab (PRO 140)"
  [2]=>
  string(154) "VANCOUVER, Washington, March 09, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-sta"
  ["short_description"]=>
  string(154) "VANCOUVER, Washington, March 09, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-sta"
  [3]=>
  string(255) "VANCOUVER, Washington, March 09, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for..."
  ["description"]=>
  string(255) "VANCOUVER, Washington, March 09, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "15"
  ["rss_id"]=>
  string(2) "15"
  [14]=>
  string(300) "https://www.drugs.com/clinical_trials/cytodyn-files-ind-protocol-phase-2-clinical-trial-coronavirus-patients-leronlimab-pro-140-18483.html?utm_source=ddc&utm_medium=rss&utm_campaign=CytoDyn+Files+IND+and+Protocol+for+Phase+2+Clinical+Trial+for+Treatment+of+Coronavirus+Patients+with+Leronlimab+%28PRO"
  ["blog_url"]=>
  string(300) "https://www.drugs.com/clinical_trials/cytodyn-files-ind-protocol-phase-2-clinical-trial-coronavirus-patients-leronlimab-pro-140-18483.html?utm_source=ddc&utm_medium=rss&utm_campaign=CytoDyn+Files+IND+and+Protocol+for+Phase+2+Clinical+Trial+for+Treatment+of+Coronavirus+Patients+with+Leronlimab+%28PRO"
  [15]=>
  string(19) "2020-03-10 07:03:21"
  ["add_date"]=>
  string(19) "2020-03-10 07:03:21"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-31 11:18:05"
  ["create_at"]=>
  string(19) "2020-03-31 11:18:05"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8044"
  ["article_id"]=>
  string(4) "8044"
  [1]=>
  string(57) "FDA Cites California Facility for Testing, Other Failures"
  ["article_title"]=>
  string(57) "FDA Cites California Facility for Testing, Other Failures"
  [2]=>
  string(153) "&#nl        The FDA issued a 14-observation Form 483 to Irvine, California drugmaker Stason Pharmaceuticals for inadequate testing and other quality fail"
  ["short_description"]=>
  string(153) "&#nl        The FDA issued a 14-observation Form 483 to Irvine, California drugmaker Stason Pharmaceuticals for inadequate testing and other quality fail"
  [3]=>
  string(168) "&#nl        The FDA issued a 14-observation Form 483 to Irvine, California drugmaker Stason Pharmaceuticals for inadequate testing and other quality failures.&#nl      "
  ["description"]=>
  string(168) "&#nl        The FDA issued a 14-observation Form 483 to Irvine, California drugmaker Stason Pharmaceuticals for inadequate testing and other quality failures.&#nl      "
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "16"
  ["rss_id"]=>
  string(2) "16"
  [14]=>
  string(96) "https://www.fdanews.com/articles/196182-fda-cites-california-facility-for-testing-other-failures"
  ["blog_url"]=>
  string(96) "https://www.fdanews.com/articles/196182-fda-cites-california-facility-for-testing-other-failures"
  [15]=>
  string(19) "2020-03-10 06:22:37"
  ["add_date"]=>
  string(19) "2020-03-10 06:22:37"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-11 16:18:24"
  ["create_at"]=>
  string(19) "2020-03-11 16:18:24"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8045"
  ["article_id"]=>
  string(4) "8045"
  [1]=>
  string(85) "Expand Safety Data for Trials of Glycemic Control in Diabetes Patients, Guidance Says"
  ["article_title"]=>
  string(85) "Expand Safety Data for Trials of Glycemic Control in Diabetes Patients, Guidance Says"
  [2]=>
  string(153) "&#nl        Sponsors of drugs to improve glycemic control in patients with Type 2 diabetes should evaluate safety data from longer-term studies and consi"
  ["short_description"]=>
  string(153) "&#nl        Sponsors of drugs to improve glycemic control in patients with Type 2 diabetes should evaluate safety data from longer-term studies and consi"
  [3]=>
  string(232) "&#nl        Sponsors of drugs to improve glycemic control in patients with Type 2 diabetes should evaluate safety data from longer-term studies and consider patients with comorbid conditions, a new FDA draft guidance says.&#nl      "
  ["description"]=>
  string(232) "&#nl        Sponsors of drugs to improve glycemic control in patients with Type 2 diabetes should evaluate safety data from longer-term studies and consider patients with comorbid conditions, a new FDA draft guidance says.&#nl      "
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "16"
  ["rss_id"]=>
  string(2) "16"
  [14]=>
  string(124) "https://www.fdanews.com/articles/196180-expand-safety-data-for-trials-of-glycemic-control-in-diabetes-patients-guidance-says"
  ["blog_url"]=>
  string(124) "https://www.fdanews.com/articles/196180-expand-safety-data-for-trials-of-glycemic-control-in-diabetes-patients-guidance-says"
  [15]=>
  string(19) "2020-03-10 06:20:57"
  ["add_date"]=>
  string(19) "2020-03-10 06:20:57"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-11 16:18:24"
  ["create_at"]=>
  string(19) "2020-03-11 16:18:24"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8100"
  ["article_id"]=>
  string(4) "8100"
  [1]=>
  string(38) "How a virus forms its symmetric shells"
  ["article_title"]=>
  string(38) "How a virus forms its symmetric shells"
  [2]=>
  string(150) "Viruses have been well studied, but many mysteries linger. One such mystery is how a spherical virus circumvents energy barriers to form symmetric she"
  ["short_description"]=>
  string(150) "Viruses have been well studied, but many mysteries linger. One such mystery is how a spherical virus circumvents energy barriers to form symmetric she"
  [3]=>
  string(325) "Viruses have been well studied, but many mysteries linger. One such mystery is how a spherical virus circumvents energy barriers to form symmetric shells. A research team has made progress is solving this mystery. The team reports that an interplay of energies at the molecular level makes the formation of a shell possible. "
  ["description"]=>
  string(325) "Viruses have been well studied, but many mysteries linger. One such mystery is how a spherical virus circumvents energy barriers to form symmetric shells. A research team has made progress is solving this mystery. The team reports that an interplay of energies at the molecular level makes the formation of a shell possible. "
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "29"
  ["rss_id"]=>
  string(2) "29"
  [14]=>
  string(62) "https://www.sciencedaily.com/releases/2020/03/200309165241.htm"
  ["blog_url"]=>
  string(62) "https://www.sciencedaily.com/releases/2020/03/200309165241.htm"
  [15]=>
  string(19) "2020-03-10 04:52:41"
  ["add_date"]=>
  string(19) "2020-03-10 04:52:41"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-11 16:23:52"
  ["create_at"]=>
  string(19) "2020-03-11 16:23:52"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8142"
  ["article_id"]=>
  string(4) "8142"
  [1]=>
  string(74) "Cushing’s Disease Drug That Novartis Sold to Recordati Nabs FDA Nod"
  ["article_title"]=>
  string(74) "Cushing’s Disease Drug That Novartis Sold to Recordati Nabs FDA Nod"
  [2]=>
  string(160) "A Cushing’s disease drug whose rights Novartis sold to Italy-based Recordati last year now has FDA approval. Cushing’s disease is a rare disorder "
  ["short_description"]=>
  string(160) "A Cushing’s disease drug whose rights Novartis sold to Italy-based Recordati last year now has FDA approval. Cushing’s disease is a rare disorder "
  [3]=>
  string(364) "A Cushing’s disease drug whose rights Novartis sold to Italy-based Recordati last year now has FDA approval. Cushing’s disease is a rare disorder in which the adrenal glands make too much of a hormone called cortisol. The Novartis (NYSE: NVS) drug, osilodrostat (Isturisa), is intended to block an enzyme key to cortisol production. The FDA […]"
  ["description"]=>
  string(364) "A Cushing’s disease drug whose rights Novartis sold to Italy-based Recordati last year now has FDA approval. Cushing’s disease is a rare disorder in which the adrenal glands make too much of a hormone called cortisol. The Novartis (NYSE: NVS) drug, osilodrostat (Isturisa), is intended to block an enzyme key to cortisol production. The FDA […]"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "36"
  ["rss_id"]=>
  string(2) "36"
  [14]=>
  string(105) "https://xconomy.com/europe/2020/03/09/cushings-disease-drug-that-novartis-sold-to-recordati-nabs-fda-nod/"
  ["blog_url"]=>
  string(105) "https://xconomy.com/europe/2020/03/09/cushings-disease-drug-that-novartis-sold-to-recordati-nabs-fda-nod/"
  [15]=>
  string(19) "2020-03-10 04:36:12"
  ["add_date"]=>
  string(19) "2020-03-10 04:36:12"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-11 16:23:57"
  ["create_at"]=>
  string(19) "2020-03-11 16:23:57"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8079"
  ["article_id"]=>
  string(4) "8079"
  [1]=>
  string(73) "SI-BONE, Inc. Reports Fourth Quarter and Full Year 2019 Financial Results"
  ["article_title"]=>
  string(73) "SI-BONE, Inc. Reports Fourth Quarter and Full Year 2019 Financial Results"
  [2]=>
  string(87) "Reiterates Full Year 2020 Financial Outlook Reiterates Full Year 2020 Financial Outlook"
  ["short_description"]=>
  string(87) "Reiterates Full Year 2020 Financial Outlook Reiterates Full Year 2020 Financial Outlook"
  [3]=>
  string(98) "Reiterates Full Year 2020 Financial Outlook 
Reiterates Full Year 2020 Financial Outlook
"
  ["description"]=>
  string(98) "Reiterates Full Year 2020 Financial Outlook 
Reiterates Full Year 2020 Financial Outlook
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "27"
  ["rss_id"]=>
  string(2) "27"
  [14]=>
  string(142) "http://www.globenewswire.com/news-release/2020/03/09/1997494/0/en/SI-BONE-Inc-Reports-Fourth-Quarter-and-Full-Year-2019-Financial-Results.html"
  ["blog_url"]=>
  string(142) "http://www.globenewswire.com/news-release/2020/03/09/1997494/0/en/SI-BONE-Inc-Reports-Fourth-Quarter-and-Full-Year-2019-Financial-Results.html"
  [15]=>
  string(19) "2020-03-10 04:05:00"
  ["add_date"]=>
  string(19) "2020-03-10 04:05:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-11 16:23:49"
  ["create_at"]=>
  string(19) "2020-03-11 16:23:49"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8322"
  ["article_id"]=>
  string(4) "8322"
  [1]=>
  string(126) "FDA Approves Ofev (Nintedanib), For The Treatment of Chronic Fibrosing Interstitial Lung Diseases with a Progressive Phenotype"
  ["article_title"]=>
  string(126) "FDA Approves Ofev (Nintedanib), For The Treatment of Chronic Fibrosing Interstitial Lung Diseases with a Progressive Phenotype"
  [2]=>
  string(150) "March 09, 2020 -- The U.S. Food and Drug Administration today approved Ofev (nintedanib) oral capsules to treat patients with chronic fibrosing (scarr"
  ["short_description"]=>
  string(150) "March 09, 2020 -- The U.S. Food and Drug Administration today approved Ofev (nintedanib) oral capsules to treat patients with chronic fibrosing (scarr"
  [3]=>
  string(244) "March 09, 2020 -- The U.S. Food and Drug Administration today approved Ofev (nintedanib) oral capsules to treat patients with chronic fibrosing (scarring) interstitial lung diseases (ILD) with a progressive phenotype (trait). It is the first..."
  ["description"]=>
  string(244) "March 09, 2020 -- The U.S. Food and Drug Administration today approved Ofev (nintedanib) oral capsules to treat patients with chronic fibrosing (scarring) interstitial lung diseases (ILD) with a progressive phenotype (trait). It is the first..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "8"
  ["rss_id"]=>
  string(1) "8"
  [14]=>
  string(300) "https://www.drugs.com/newdrugs/fda-approves-ofev-nintedanib-chronic-fibrosing-interstitial-lung-diseases-progressive-phenotype-5181.html?utm_source=ddc&utm_medium=rss&utm_campaign=FDA+Approves+Ofev+%28Nintedanib%29%2C+For+The+Treatment+of+Chronic+Fibrosing+Interstitial+Lung+Diseases+with+a+Progressi"
  ["blog_url"]=>
  string(300) "https://www.drugs.com/newdrugs/fda-approves-ofev-nintedanib-chronic-fibrosing-interstitial-lung-diseases-progressive-phenotype-5181.html?utm_source=ddc&utm_medium=rss&utm_campaign=FDA+Approves+Ofev+%28Nintedanib%29%2C+For+The+Treatment+of+Chronic+Fibrosing+Interstitial+Lung+Diseases+with+a+Progressi"
  [15]=>
  string(19) "2020-03-10 04:03:11"
  ["add_date"]=>
  string(19) "2020-03-10 04:03:11"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-19 11:28:43"
  ["create_at"]=>
  string(19) "2020-03-19 11:28:43"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8533"
  ["article_id"]=>
  string(4) "8533"
  [1]=>
  string(134) "FDA Approves Ofev (nintedanib) as First Treatment for Chronic Fibrosing Interstitial Lung Diseases (ILDs) with a Progressive Phenotype"
  ["article_title"]=>
  string(134) "FDA Approves Ofev (nintedanib) as First Treatment for Chronic Fibrosing Interstitial Lung Diseases (ILDs) with a Progressive Phenotype"
  [2]=>
  string(150) "Ridgefield, Conn., March 9, 2020 – Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) approved Ofev "
  ["short_description"]=>
  string(150) "Ridgefield, Conn., March 9, 2020 – Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) approved Ofev "
  [3]=>
  string(250) "Ridgefield, Conn., March 9, 2020 – Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) approved Ofev (nintedanib) as the first treatment for people with chronic fibrosing interstitial lung diseases..."
  ["description"]=>
  string(250) "Ridgefield, Conn., March 9, 2020 – Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) approved Ofev (nintedanib) as the first treatment for people with chronic fibrosing interstitial lung diseases..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "8"
  ["rss_id"]=>
  string(1) "8"
  [14]=>
  string(300) "https://www.drugs.com/newdrugs/fda-approves-ofev-nintedanib-first-chronic-fibrosing-interstitial-lung-diseases-ilds-progressive-5181.html?utm_source=ddc&utm_medium=rss&utm_campaign=FDA+Approves+Ofev+%28nintedanib%29+as+First+Treatment+for+Chronic+Fibrosing+Interstitial+Lung+Diseases+%28ILDs%29+with+"
  ["blog_url"]=>
  string(300) "https://www.drugs.com/newdrugs/fda-approves-ofev-nintedanib-first-chronic-fibrosing-interstitial-lung-diseases-ilds-progressive-5181.html?utm_source=ddc&utm_medium=rss&utm_campaign=FDA+Approves+Ofev+%28nintedanib%29+as+First+Treatment+for+Chronic+Fibrosing+Interstitial+Lung+Diseases+%28ILDs%29+with+"
  [15]=>
  string(19) "2020-03-10 04:03:11"
  ["add_date"]=>
  string(19) "2020-03-10 04:03:11"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-31 11:18:00"
  ["create_at"]=>
  string(19) "2020-03-31 11:18:00"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}